1. Academic Validation
  2. Phase-separating peptides for direct cytosolic delivery and redox-activated release of macromolecular therapeutics

Phase-separating peptides for direct cytosolic delivery and redox-activated release of macromolecular therapeutics

  • Nat Chem. 2022 Mar;14(3):274-283. doi: 10.1038/s41557-021-00854-4.
Yue Sun 1 Sze Yi Lau 2 Zhi Wei Lim 1 Shi Chieh Chang 3 Farid Ghadessy 2 Anthony Partridge 3 Ali Miserez 4 5
Affiliations

Affiliations

  • 1 Biological and Biomimetic Material Laboratory (BBML), Center for Sustainable Materials (SusMat), School of Materials Science and Engineering, Nanyang Technological University (NTU), Singapore, Singapore.
  • 2 p53 Laboratory, Agency for Science, Technology and Research (A*STAR), Neuros/Immunos, Singapore, Singapore.
  • 3 Translation Medicine Research Centre, MSD International, Singapore, Singapore.
  • 4 Biological and Biomimetic Material Laboratory (BBML), Center for Sustainable Materials (SusMat), School of Materials Science and Engineering, Nanyang Technological University (NTU), Singapore, Singapore. [email protected].
  • 5 School of Biological Sciences, NTU, Singapore, Singapore. [email protected].
Abstract

Biomacromolecules are highly promising therapeutic modalities to treat various diseases. However, they suffer from poor cellular membrane permeability, limiting their access to intracellular targets. Strategies to overcome this challenge often employ nanoscale carriers that can get trapped in endosomal compartments. Here we report conjugated Peptides that form pH- and redox-responsive coacervate microdroplets by liquid-liquid phase separation that readily cross the cell membrane. A wide range of macromolecules can be quickly recruited within the microdroplets, including small Peptides, enzymes as large as 430 kDa and messenger RNAs (mRNAs). The therapeutic-loaded coacervates bypass classical endocytic pathways to enter the cytosol, where they undergo glutathione-mediated release of payload, the bioactivity of which is retained in the cell, while mRNAs exhibit a high transfection efficiency. These peptide coacervates represent a promising platform for the intracellular delivery of a large palette of macromolecular therapeutics that have potential for treating various pathologies (for example, cancers and metabolic diseases) or as carriers for mRNA-based vaccines.

Figures
Products